To maintain hemostasis or to stop bleeding in Hemophilia A and mild-to-moderate Type I von Willebrand Disease (VWD), each with Factor VIII levels >5%.
<11months: not recommended. Give test dose prior to initiating therapy. >11months: <50kg: 1 spray in one nostril (150mcg). ≥50kg: 1 spray per nostril (300mcg). May repeat dose based on clinical response. Pre-op: give 2hrs prior to procedure. Repeated administration before 48 hrs associated with tachyphylaxis.
Not for treating Type IIb VWD, or severe VWD with abnormal molecular form of Factor VIII antigen. Adjust fluid intake downward (esp in children and elderly) to reduce risk of water intoxication, hyponatremia. Monitor fluid intake, plasma osmolality. Fluid and electrolyte imbalances (eg, cystic fibrosis). Coronary artery disease. Hypertension. Predisposition to thrombosis. Unreliable absorption if altered nasal mucosa (eg, scarring, edema); discontinue until resolved. Pregnancy (Cat.B). Nursing mothers.
Caution with other pressor agents (monitor).
Headache, nausea, abdominal cramps, vulval pain, facial flushing, local reactions, sore throat, water intoxication, hyponatremia; rare: BP changes, severe allergic reactions, thrombotic events.
Spray Pump—2.5mL (25 sprays)